Literature DB >> 30788714

Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer.

Mickey S Ising1,2, Katy Marino2, Jaimin R Trivedi2, Adam A Rojan3, Neal E Dunlap4, Victor van Berkel2, Matthew P Fox5.   

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy followed by resection is standard of care for patients with locally advanced esophageal cancer, however, a significant portion of these patients do not undergo surgical intervention. This study evaluates radiation dose and other factors associated with undergoing esophageal resection and their impact on outcomes including survival.
METHODS: Patients diagnosed with esophageal cancer between 2010 and 15 were queried from the National Cancer Database and stratified into low-dose radiation (41.4 Gy) (LDR) or high-dose radiation (50.0 or 50.4 Gy) (HDR) groups. Multivariable Logistic and Cox Regression analyses were performed to investigate the effect of multiple variables on the likelihood of undergoing esophagectomy and overall survival, respectively. Propensity score matching was performed to reduce bias between groups.
RESULTS: A total of 3633 patients met study criteria with 3005 (82.7%) undergoing esophagectomy. A greater proportion received HDR (3163 (87.1%)) than LDR (470 (12.9%)). The use of LDR increased from 4.7% (n = 22) in 2010 to 20.7% (n = 154) in 2015. Factors associated with undergoing esophagectomy included LDR, adenocarcinoma histology, and younger age. Radiation dosage did not impact overall survival, but undergoing esophagectomy was associated with improved survival. After propensity matching, a greater portion of the LDR group underwent esophagectomy (87.0 vs 81.1%, p = 0.013). There was no difference in R0 3 resection (93.2 vs 92.4%, p = 0.678) or complete pathologic response (19.3 vs 21.5%, p = 0.442) between LDR and HDR groups.
CONCLUSION: The use of LDR is increasing but still underutilized. LDR is associated with increased rates of esophagectomy without negatively impacting overall survival, R0 resection, or complete pathologic response.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Radiation dosage

Mesh:

Year:  2019        PMID: 30788714     DOI: 10.1007/s11605-019-04141-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.

Authors:  Lisa A Kachnic; Kathryn Winter; Todd Wasserman; David Kelsen; Robert Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; Christopher G Willett; Bruce D Minsky
Journal:  Gastrointest Cancer Res       Date:  2011-03

2.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

Authors:  A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

3.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

Authors:  Susan L Tucker; H Helen Liu; Shulian Wang; Xiong Wei; Zhongxing Liao; Ritsuko Komaki; James D Cox; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-11       Impact factor: 7.038

5.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Authors:  Laurent Bedenne; Pierre Michel; Olivier Bouché; Chantal Milan; Christophe Mariette; Thierry Conroy; Denis Pezet; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Bernard Paillot; Patrick Arveux; Franck Bonnetain; Christine Binquet
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

6.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Authors:  Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters.

Authors:  Hoon K Lee; Ara A Vaporciyan; James D Cox; Susan L Tucker; Joe B Putnam; Jaffer A Ajani; Zhongxing Liao; Stephen G Swisher; Jack A Roth; W Roy Smythe; Garrett L Walsh; Radhe Mohan; Hui H Liu; Deidre Mooring; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

8.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.

Authors:  Nikhil I Khushalani; Cynthia Gail Leichman; Gary Proulx; Hector Nava; Lisa Bodnar; Donald Klippenstein; Alan Litwin; Judy Smith; Enriqueta Nava; Lakshmi Pendyala; Patrick Smith; William Greco; Joanne Berdzik; Harold Douglass; Lawrence Leichman
Journal:  J Clin Oncol       Date:  2002-06-15       Impact factor: 44.544

View more
  3 in total

1.  Radiation doses in esophageal cancer.

Authors:  Susan A Smith; Matthew P Fox
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

Review 2.  Advances in the curative management of oesophageal cancer.

Authors:  Jarlath C Bolger; Claire L Donohoe; Maeve Lowery; John V Reynolds
Journal:  Br J Cancer       Date:  2021-10-21       Impact factor: 7.640

3.  Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma.

Authors:  Chu-Pin Pai; Ling-I Chien; Chien-Sheng Huang; Han-Shui Hsu; Po-Kuei Hsu
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.